Skip to main content
SpringerLink
Log in

Klinisch-Neuropsychologische Aspekte der Therapie mit Psychopharmaka

  • Chapter
Neuropsychologie psychischer Störungen

Zusammenfassung

Ein 37-jähriger Patient, verheiratet, Vater von zwei Kindern, seit 5 Wochen in psychiatrischer Behandlung aufgrund einer rezidivierenden depressiven Störung ohne somatische Symptome, kommt kurz vor Entlassung aus der stationären Behandlung zur neuropsychologischen Untersuchung mit der Fragestellung der beruflichen Wiedereingliederung. Als selbständiger Versicherungskaufmann ist er auf sein Kraftfahrzeug angewiesen, er hat täglich mehrere Kundenkontakte, in denen neben selbstsicherem Auftreten erwartet wird, dass er kompetent auch zu komplexen Fragen Stellung beziehen kann. Mit dem Kraftfahrzeug legt er berufsbedingt täglich oftmals mehr als 200 km zurück. Zur Untersuchung kommt er unter medikamentösen Steady-state-Bedingungen (Citalopram 40 mg); die depressive Symptomatik ist weitgehend remittiert (HAMD-17=12). Im Anamnesegespräch gibt er zu verstehen, dass er die Befürchtung habe, dass trotz deutlicher Verbesserung der affektiven Symptomatik seine Leistungsfähigkeit noch beeinträchtigt sei.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

25.8 Literatur

  • Alexopoulos GS, Kiosses DN, Klimstra S et al. (2002) Clinical presentation of the „depression-executive-dysfunction-syndrome“ of late life. Am J Geriatr Psychiatry 10: 98–106

    PubMed  Google Scholar 

  • Amado-Boccara I, Gougoulis N, Poirier Littre MF et al. (1995) Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 19: 479–493

    PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2005) Empfehlungen zur Therapie der Demenz. Arzneiverordnung in der Praxis. 3.Aufl., Köln

    Google Scholar 

  • Barbee JG (1993) Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry 54 (suppl 10): 86–97, discussion 98–101

    PubMed  Google Scholar 

  • Barbone F, McMahon A, Davey P et al. (1998) Association of road-traffic accidents with benzodiazepine use. Lancet 352: 1331–1336

    PubMed  Google Scholar 

  • Barker MJ, Greenwood KM, Jackson M et al. (2004a) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18: 37–48

    PubMed  Google Scholar 

  • Barker MJ, Greenwood KM, Jackson M et al. (2004b) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19: 437–454

    PubMed  Google Scholar 

  • Bilder RM, Goldman RS, Robinson D et al. (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry 157: 549–559

    PubMed  Google Scholar 

  • Bilder RM, Goldman RS, Volavka J et al.(2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018–1028

    PubMed  Google Scholar 

  • Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews 1: CD005593

    Google Scholar 

  • Birks J, Flicker L (2003) Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev 1: CD000442

    PubMed  Google Scholar 

  • Birks J, Grimley EV, Van Dongen M (2002) Gingko biloba for cognitive impairment in dementia. Cochrane Database Syst Rev 4: CD003120

    PubMed  Google Scholar 

  • Bowie CR, Harvey PD (2006) Treatment of cognitive deficits in schizophrenia. Curr Opin Investig Drugs 7: 608–613

    PubMed  Google Scholar 

  • Brunnauer A, Laux G (2006) Fahrtüchtigkeit, schizophrene Psychosen und Neuroleptika. In: M Schmauß (Hrsg.) Schizophrenie — Pathogenese, Diagnostik und Therapie. UNI-MED Verlag AG Bremen (383–392)

    Google Scholar 

  • Brunnauer A, Laux G, Geiger E et al. (2006) Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 67: 1776–1781

    PubMed  Google Scholar 

  • Buchanan RW, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36:717–725

    PubMed  Google Scholar 

  • Buffet-Jerrot SE, Stewart SH, Bird S et al. (1998) An examination of differences in the time course of oxazepam’s effects on implicit vs. explicit memory. J Psychopharmacol 12: 338–347

    Google Scholar 

  • Cassano GB, Puca F, Scappichio PL et al. (2002) Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 63: 396–402

    PubMed  Google Scholar 

  • Corey-Bloom J, Anand R, Veach J (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acethylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65

    Google Scholar 

  • Cowley DS, Roy-Byrne PP, Radant A et al. (1995) Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 12: 147–157

    PubMed  Google Scholar 

  • Cuesta MJ, Peralta V, Zarzuela A (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48: 17–28

    PubMed  Google Scholar 

  • Curran HV, Sakulsripong M, Lader M (1988) Antidepressants and human memory: An investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacol 95: 520–527

    Google Scholar 

  • Curran HV, Schiwy W, Lader M (1987) Differential amnestic effects of benzodiazepines: A dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacol 92: 358–364

    Google Scholar 

  • Curran HV (1986) Tranquilising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 23: 179–213

    PubMed  Google Scholar 

  • Currie D, Hashemi K, Fothergill J et al. (1995) The use of antidepressants and benzodiazepines in the perpetrators and victims of accident. Occup Med (Lond) 45: 323–325

    Google Scholar 

  • Doraiswamy PM, Krishnan KR, Oxman T et al. (2003) Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci 58: 1137–1144

    Google Scholar 

  • Dubini A, Bosc M, Polin V (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 11: 17–23

    Google Scholar 

  • Edwards JG (1995) Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants. CNS Drugs 4: 141–159

    Google Scholar 

  • Fagerlund B, Mackeprang D, Gade A et al. (2004) Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first episode drug naive schizophrenic patients. CNS Spectr 9: 364–374

    PubMed  Google Scholar 

  • Förstl H (2003) Antidementiva. Urban & Fischer, München Gladsjo JA, Rapaport MH, McKinney R et al. (2001) Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J Clin Psychopharmacol 21: 131–138

    Google Scholar 

  • Good KP, Kiss I, Buiteman C et al. (2002) Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 43: 45–49

    Google Scholar 

  • Goldberg TE, Greenberg RD, Griffin SJ et al. (1993) The effects of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162: 43–48

    PubMed  Google Scholar 

  • Goldberg TE, Gold JM (1995) Neurocognitive functioning in patients with schizophrenia. In: FE Bloom, DJ Kupfer Hrsg Psychopharmacology —The fourth generation of progress. Raven Press, New York, 1245–1257

    Google Scholar 

  • Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 151: 357–362

    Google Scholar 

  • Green MF (2002) Recent studies on the neurocognitive effects of second generation antipsychotic medications. Curr Opin Psychiatry 15: 25–29

    Google Scholar 

  • Green MF, Marshal BD Jr, Wirshing WC et al. (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799–804

    PubMed  Google Scholar 

  • Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res 72: 41–51

    PubMed  Google Scholar 

  • Hoch I, Rentsch A, Krappweis J et al. (2004) Psychopharmakaverordnungen an älteren Menschen. Ein Vergleich zwischen Patienten aus Alten-und Pflegeheimen, ambulant behandelten Pflegefällen und ambulanten Patienten ohne Pflegebedarf. Z Gerontol Geriat 37: 214–220

    Google Scholar 

  • Häussler B, Höer A, Hempel E et al. (2007) Arzneimittel-Atlas 2006. Die Entwicklung des Arzneimittelverbrauchs in der GKV. Urban & Vogel, München

    Google Scholar 

  • Hagger C, Buckley P, Kenny JT et al. (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702–712

    PubMed  Google Scholar 

  • Hamilton SH, Edgell ET, Revicki DA et al. (2000) Functional outcomes in schizophrenia. A comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 15: 245–255

    PubMed  Google Scholar 

  • Harvey PD, Siu CO, Romano S (2004a) Randomized, controlled, doubleblind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 172: 324–332

    Google Scholar 

  • Harvey PD, Meltzer H, Simpson GM et al. (2004b) Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66: 101–113

    PubMed  Google Scholar 

  • Hemmelgarn B, Suissa S, Huang A et al. (1997) Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 278: 27–31

    PubMed  Google Scholar 

  • Herrschaft H (2001) Antidementiva in der Praxis — Pharmakologie, Indikationen, Therapie. Uni-Med, Bremen

    Google Scholar 

  • Hirschfeld RMA, Montgomery SA, Keller MB et al. (2000). Social functioning in depression: a review. J Clin Psychiatry 61: 268–275

    PubMed  Google Scholar 

  • Hindmarch I (1995) The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 9: 13–17

    PubMed  Google Scholar 

  • Kasper S, Resinger E (2003) Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 28: 27–38

    PubMed  Google Scholar 

  • Keefe RSE, Silva SG, Perkins DO, Liebermann J (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201–222

    PubMed  Google Scholar 

  • Keefe RS, Seidmann LJ, Christensen BK et al. (2006) Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first episode psychosis. Biol Psychiatry 59: 97–105

    PubMed  Google Scholar 

  • Kern RS, Green MF, Cornblatt BA et al. (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187: 312–320

    Google Scholar 

  • Kern RS, Green MF, Marshall BD et al. (1998) Risperidone vs. Haloperidol on reaction time, manual dexterity, and motor learning in treatment resistant schizophrenia patients. Biol Psychiatry 44: 726–732

    PubMed  Google Scholar 

  • Kerr JS, Hindmarch I (1996) Citalopram and other antidepressants: Comparative effects on cognitive function and psychomotor performance. Journal of Serotonin Research 3: 123–129

    Google Scholar 

  • Kessler H, Supprian T, Rösler M (2003) Antidementive Pharmakotherapie. Ein Update. Psychopharmakotherapie 10: 132–140

    Google Scholar 

  • Kilic C, Curran HV, Noshirvani H et al. (1999) Long term effects of alprazolam on memory: a 3.5 year follow up of agoraphobia/panic patients. Psychol Med 29: 225–231

    PubMed  Google Scholar 

  • Klotz U, Laux G (1996) Tranquillantien. Therapeutischer Einsatz und Pharmakologie. 2. Aufl. Wiss Verlagsges Stuttgart

    Google Scholar 

  • Knegtering H, Eijck M, Huijsman A (1994) Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging 5: 192–199

    PubMed  Google Scholar 

  • Kocsis JH, Zisook S, Davidson J et al. (1997) Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes. Am J Psychiatry 154: 390–395

    PubMed  Google Scholar 

  • van Laar M, Volkerts E (1998) Driving and benzodiazepine use. CNS Drugs 10: 383–396

    Google Scholar 

  • Lagnaoui R, Begaud B, Moore N et al. (2002) Benzodiazepine use and risk of dementia: a nested case-control sudy. J Clin Epidemiol 55: 314–318

    PubMed  Google Scholar 

  • Lane RM, O’Hanlon JF (1999) Cognitive and psychomotor effects of antidepressants with emphasis on selective serotonin reuptake inhibitors and the depressed elderly patient. German Journal of Psychiatry 2:1–42

    Google Scholar 

  • Laux G (1995) Aktueller Stand der Therapie mit Benzodiazepinen. Eine Übersicht. Nervenarzt 66: 311–322

    Google Scholar 

  • Laux G (2010) Nomenklatur, Einteilung von Psychopharmaka. In: P Riederer, G Laux (Hg.) Grundlagen der Neurospychopharmakologie. Wien: Springer. S. 353–367.

    Google Scholar 

  • Laux G, Dietmaier O (2006) Praktische Psychopharmakotherapie. Urban & Fischer Verlag, München, Jena

    Google Scholar 

  • Le Bars PL, Katz MM, Berman N et al. (1997) A placebo-controlled, doubleblind, randomized trial of an extract of Gingko biloba for dementia. JAMA 278: 1327–1332

    PubMed  Google Scholar 

  • Leveille SG, Buchner DM, Koepsell TD et al. (1994) Psychoactive medications and injurious motor vehicle collissions involving older drivers. Epidemiology 5: 591–598

    PubMed  Google Scholar 

  • Lewrenz H (2000) Begutachtungs-Leitlinien zur Kraftfahrereignung. Wirtschaftsverlag, Bremerhaven

    Google Scholar 

  • Lister RG, File SE (1984) The nature of lorazepam-induced amnesia. Psychopharmacol 83: 183–187

    Google Scholar 

  • McGurk S R, Lee MA, Jayathilake K et al. (2004) Cognitive effects of olanzapine treatment in schizophrenia. Med Gen Med 10: 27

    Google Scholar 

  • McShane R, Areosa Sastre A, Minakaran N (2006). Memantine for dementia. Cochrane Database Syst Rev 19: CD003154

    Google Scholar 

  • Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive functioning in schizophrenia. Schiophr Bull 25: 233–255

    Google Scholar 

  • Mishara A L, Goldberg TE (2004) A meta analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013–1022

    PubMed  Google Scholar 

  • Mowia A, Mosavinasab M, Pani A (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment?: a double blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27: 67–70

    Google Scholar 

  • Möller HJ (2000) Are all antidepressants the same? J Clin Psychiatry 61: 24–28

    PubMed  Google Scholar 

  • Müller WE (1995) Benzodiazepine. Experimentelle und klinische Pharmakologie. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka. Ein Therapie-Handbuch. Bd. 2 Tranquilizer und Hypnotika. Springer, Wien

    Google Scholar 

  • Müller U, Fletcher PC, Steinberg H (2006) The origin of pharmacopsychology: Emil Kraepelin’s experiments in Leipzig, Dorpat and Heidelberg (1882–1892). Psychopharmacology 184: 131–138

    PubMed  Google Scholar 

  • Naber D, Lambert M, Krausz M et al. (2002) Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2.Aufl. Uni-Med, Bremen

    Google Scholar 

  • Nathan PJ, Sitaram G, Stough C et al. (2000) Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol 11: 639–642

    PubMed  Google Scholar 

  • Paterniti S, Duffouil C, Alperovitch A (2002) Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 22: 285–293

    PubMed  Google Scholar 

  • Petersen RC, Thomas RG, Grundmann M et al. (2005) Vitamin E and Donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388

    PubMed  Google Scholar 

  • Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitiv dysfunction in schizophrenia. Clin Ther 27: S25–S37

    PubMed  Google Scholar 

  • Potter GG, Kittinger JD, Wagner HR, Steffens DC, Krishnan KR (2004) Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 29: 2226–2271

    Google Scholar 

  • Purdon SE, Jones BDW, Stip E et al. (2000) Neuropsychological change in early phase schizophrenia during 12 month of treatment with olanzapine, risperidone, or haloperidole. Arch Gen Psychiatr 57: 249–258

    PubMed  Google Scholar 

  • Purdon SE, Malla A, Labelle A et al. (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137–149

    PubMed  Google Scholar 

  • Ramaekers JG (2003) Antidepressants and driver impairment: emprirical evidence from a standard on-the-road test. J Clin Psychiatry 64: 20–29

    PubMed  Google Scholar 

  • Ray WA, Fought WL, Decker MD (1992) Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 136: 873–883

    PubMed  Google Scholar 

  • Riederer P, Laux G, Pöldinger W (Hrsg) (2002) Neuro-Psychopharmaka. Ein Therapie-Handbuch. Bd. 3 Antidepressiva. 2.Aufl. Springer, Wien

    Google Scholar 

  • Rocca P, Calvarese P, Fagiano F et al. (2005). Citalopram versus sertraline in late life nonmajor clinically significant depression: a 1-year followup clinical trial. J Clin Psychiatry 66: 360–369

    PubMed  Google Scholar 

  • Rossi A, Manchini F, Stratta P et al. (1997) Risperidone, negative symptoms and cognitive deficits in schizophrenia: an open study. Acta Psychiatr Scand 95: 40–43

    PubMed  Google Scholar 

  • Sax KW, Strakowski SM, Keck PE (1998) Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 33: 151–155

    PubMed  Google Scholar 

  • Schwabe, U., Paffrath, D. (Hrsg.) (2009): Arzneiverordnungs-Report 2008. Springer, Heidelberg.

    Google Scholar 

  • Simpson SW, Baldwin RC, Burns A et al. (2001) Regional cerebral volume measurements in late-life depression: relationship to clinical correlates, neuropsychological impairment and response to treatment. Int J Geriatr Psychiatry 16: 469–476

    PubMed  Google Scholar 

  • Stein RA, Strickland TL (1998) A review of the neuropsychological effects of commonly used prescription medications. Arch Clin Neuropsychol 13: 258–284

    Google Scholar 

  • Stratta P, Donda P, Rossi A et al. (2005) Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study. Hum Psychopharmacol 20: 401–408

    PubMed  Google Scholar 

  • Tabet N, Birks J, Grimley Evans J (2000) Vitamin E for Alzheimer’s disease. Cochrane Database Syst Review 4: CD002854

    Google Scholar 

  • Tamminga CA (2006) The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67 (supplement 9): 9–13

    PubMed  Google Scholar 

  • Tariot PN, Solomon PR, Morris JC et al. (2000) A 5-month, randomized, plazebo-controlled trial of galantamine in AD. Neurology 54: 2269–2276

    PubMed  Google Scholar 

  • Tölle, R, Schott H (2010) Historischer Abriss: Geschichte der Psychopharmaka. In P Riederer, G Laux (Hg.) Grundlagen der Neuropsychopharmakologie. Wien: Springer. S. 11–29.

    Google Scholar 

  • Velligan DI, Prihoda DJ, Sui D et al. (2003) The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 64: 524–531

    PubMed  Google Scholar 

  • Velligan DI, Newcomer J, Pultz J et al. (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53: 239–248

    PubMed  Google Scholar 

  • Verdoux H, Lagnaoui R, Begaud B (2004) Is benzodiazepine use a risk factor for cognitive decline and dementia ? A literature review of epidemiological data. Psychol Med 35: 307–315

    Google Scholar 

  • Verster JC, Veldhuijzen DS, Volkerts RE (2004) Residual effect of sleep medication on driving ability: Sleep Med Rev 8: 309–325

    PubMed  Google Scholar 

  • Wagner M, Quednow BB, Westheide J et al. (2005) Cognitive improvement in schizophrenia does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30: 381–390

    PubMed  Google Scholar 

  • Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int Geriat Psychiatry 14: 135–146

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inn-Salzach-Klinikum Neuropsychologie, Gabersee 7, 83512, Wasserburg/Inn

    Dr. Alexander Brunnauer & Prof. Dr. Gerd Laux

Authors
  1. Dr. Alexander Brunnauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Gerd Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lehrstuhl für Physiologische Psychologie, Otto-Friedrich-Universität Bamberg, Markusplatz 3, 96045, Bamberg

    Stefan Lautenbacher

  2. Institut für Medizinische Psychologie und Soziologie, RWTH Aachen, Pauwelsstraße 30, 52074, Aachen

    Siegfried Gauggel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Brunnauer, A., Laux, G. (2010). Klinisch-Neuropsychologische Aspekte der Therapie mit Psychopharmaka. In: Lautenbacher, S., Gauggel, S. (eds) Neuropsychologie psychischer Störungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72340-0_25

Download citation

Publish with us

Policies and ethics

Search

Navigation